Clinical Trials on IgG4-Related Disease

Total 386969 results

National Institute on Drug Abuse (NIDA)
Mclean Hospital

Completed

Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

Heroin Dependence | Cocaine-Related Disorders

United States
Nemours Children's Clinic
Genentech, Inc.

Completed

Nutrients and Hormones: Effects in Boys With Disordered Growth

Nutrition Disorders | Growth Disorders | Constitutional Growth Delay

United States
Federal University of São Paulo

Completed

Stem Cell Therapy for Outer Retinal Degenerations

Age Related Macular Degeneration | Exudative Age-related Macular Degeneration | Stargardt's Disease

Brazil
South West Sydney Local Health District
National Health and Medical Research Council, Australia; University of Sydney

Completed

Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease (BacALD)

Alcohol Dependence | Alcoholic Liver Disease

Australia
Inventage Lab., Inc.

Not yet recruiting

A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3004

Alcohol Dependence | Opioid Dependence
University of Pittsburgh
National Institute on Drug Abuse (NIDA)

Enrolling by invitation

STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy (STEPuP)

Pregnancy Related | Opioid-use Disorder

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Lade Addiction Treatment Center

Completed

Oxytocin and Alcohol Withdrawal and Dependence

Substance-Related Disorders | Alcoholism

Norway
Centre for Addiction and Mental Health

Completed

Melatonin Use for Sleep Problems in Alcohol Dependent Patients

Alcohol-Related Disorders

Canada
GlaxoSmithKline
University of Cambridge

Completed

GSK1521498 Alcohol Interaction Study

Alcoholism

United States
Mayo Clinic
Samuel C. Johnson Foundation

Completed

Acamprosate: Genes Associated With Response (ACAM)

Alcoholism

United States
Pfizer

Completed

Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo

Chronic Pain | Analgesia | Opioid-related Disorders | Narcotic Abuse
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca; University of Cambridge

Terminated

A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems (PRIME)

Drug-Related Side Effects and Adverse Reactions | Cardiovascular System Disease

United Kingdom
Hospital General Universitario Gregorio Marañon

Terminated

Ethanol in the Prevention of Central Venous Catheter Infections

Catheter Related Infection

Spain
University Hospital, Montpellier

Completed

Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.

Alcoholism | Alcohol Use Disorder | Alcohol; Liver

France
Institute of Child Health

Completed

CATCH - Catheter Infections in Children

Catheter-related Infections

United Kingdom
Chengdu University of Traditional Chinese Medicine

Recruiting

EA for Protracted Withdrawal of OUD

Opioid-Related Disorders

China
West Virginia University
National Institute on Drug Abuse (NIDA); Medtronic

Active, not recruiting

Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder (DBS_OUD)

Opioid-Related Disorders

United States
University of Washington
National Institute on Drug Abuse (NIDA); emocha Mobile Health, Inc.

Completed

Trial of Adherence App for Buprenorphine Treatment (TAAB) Study

Opioid-Related Disorders

United States
Potomac Health Foundations

Completed

Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone (YORS)

Opioid-Related Disorders

United States
University of Michigan
Centers for Disease Control and Prevention

Completed

The OPT-IN Project

Opioid-Related Disorders

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Maintenance for Opioid Addicts - 1

Opioid-Related Disorders

United States
Acura Pharmaceuticals Inc.

Completed

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Terminated

Pioglitazone to Treat Opioid Withdrawal Symptoms

Opioid-Related Disorders

United States
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)

Completed

Stress and Medication Effects on Cocaine Cue Reactivity

Cocaine Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
Johns Hopkins University

Terminated

Abuse Potential of Buprenorphine/Naloxone

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Completed

Tramadol to Reduce Opioid Withdrawal Symptoms

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Completed

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Terminated

Interactions Between Intravenous (IV) Cocaine and Lofexidine

Cocaine Related Disorders

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Maintenance Protocol - 1

Opioid-Related Disorders

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

Multicenter Clinical Trial of Buprenorphine - 3

Opioid-Related Disorders

United States
University of Vermont
National Institute on Drug Abuse (NIDA)

Completed

Alternate Day Buprenorphine Administration, Phase XI - 16

Opioid-Related Disorders

United States
Yale University
National Institute on Drug Abuse (NIDA)

Withdrawn

Neurobiology of Opioid Dependence: 4 - 4

Opioid-Related Disorders

United States
University of Vermont
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Dose Alteration Study - 1

Opioid-Related Disorders

United States
University of Vermont
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

Opioid-Related Disorders

United States
University of Vermont
National Institute on Drug Abuse (NIDA)

Completed

Alternate Day Buprenorphine Administration, Phase IX - 14

Opioid-Related Disorders

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2

Opioid-Related Disorders

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Long-term Behavior Change - 1

Amphetamine-related Disorders

United States
Yale University
National Institute on Drug Abuse (NIDA)

Withdrawn

Neurobiology of Opioid Dependence: 1 - 1

Opioid-Related Disorders

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1

Opioid-Related Disorders

United States
Indivior Inc.

Completed

Safety and Tolerability of Buprenorphine/Naloxone Film Strips

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
University of Vermont

Completed

Buprenorphine Detoxification - BBDVI - 19

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine Combination Tablet Feasibility - 1

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
University of Vermont

Completed

Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
University of Vermont

Completed

Buprenorphine Pharmacology Related to Addiction Treatment - 18

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
University of Vermont

Completed

Alternate-Day Buprenorphine Administration. Phase I - 3

Opioid-Related Disorders

United States
National Institute on Drug Abuse (NIDA)
University of Vermont

Completed

Alternate-Day Buprenorphine. Phase V - 6

Opioid-Related Disorders

United States
University Hospital, Angers

Completed

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study) (IMPROVE)

NAFLD | Liver Fibrosis | Alcohol-Related Disorder

France
Novartis Pharmaceuticals

Recruiting

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (EPIK-P2)

PIK3CA-related Overgrowth Spectrum (PROS)

United States, Canada, Spain, Switzerland, France, United Kingdom, Germany, Italy, China, Hong Kong, Netherlands, Norway
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (EPIK-P3)

PIK3CA-related Overgrowth Spectrum (PROS)

Spain, France, Ireland, United States

Clinical Trials on IgG4-Related Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations